Please use this identifier to cite or link to this item:
https://doi.org/10.1038/bmt.2010.14
Title: | The role of allogeneic SCT in primary myelofibrosis: A British Society for Blood and Marrow Transplantation study | Authors: | Stewart, W.A. Pearce, R. Kirkland, K.E. Bloor, A. Thomson, K. Apperley, J. McQuaker, G. Marks, D.I. Craddock, C. McCann, S. Russell, N. Cook, G. Kottaridis, P.D. |
Keywords: | myeloablative conditioning regimens myelofibrosis reduced-intensity conditioning regimens SCT |
Issue Date: | 7-Nov-2010 | Citation: | Stewart, W.A., Pearce, R., Kirkland, K.E., Bloor, A., Thomson, K., Apperley, J., McQuaker, G., Marks, D.I., Craddock, C., McCann, S., Russell, N., Cook, G., Kottaridis, P.D. (2010-11-07). The role of allogeneic SCT in primary myelofibrosis: A British Society for Blood and Marrow Transplantation study. Bone Marrow Transplantation 45 (11) : 1587-1593. ScholarBank@NUS Repository. https://doi.org/10.1038/bmt.2010.14 | Abstract: | Fifty-one patients with primary myelofibrosis (PMF) received allogeneic haematopoietic stem cell transplants from related (n=33) or unrelated (n=18) donors. Twenty-seven patients, 19-54 years old, were prepared with myeloablative regimens including CY plus BU (n=4) or TBI (n=23). Twenty-four patients, 40-64 years old, received reduced-intensity conditioning (RIC) regimens. All RIC regimens contained fludarabine, combined with melphalan (n=19) or BU (n=5), and alemtuzumab or anti-thymocyte globulin (ATG) in the majority (n=19). Four patients (17%) in the RIC group had primary graft failure. Previous splenectomy reduced time to engraftment in the RIC group (13 versus 20 days; P=0.008). For MA and RIC groups, respectively, at 3 years, overall survival rates were 44 and 31% (P=0.67), progressionfree survival 44 and 24% (P=0.87), and actuarial relapse rates 15 and 46% (P=0.06). Non-relapse mortality at 3 years was 41% for the myeloablative and 32% for the RIC group. Acute GVHD occurred in 29 and 38% of patients in the myeloablative and RIC groups, respectively. Extensive chronic GVHD developed in 30 and 35% of evaluable patients, respectively. © 2010 Macmillan Publishers Limited. All rights reserved. | Source Title: | Bone Marrow Transplantation | URI: | http://scholarbank.nus.edu.sg/handle/10635/126292 | ISSN: | 02683369 | DOI: | 10.1038/bmt.2010.14 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.